Source: Eur Respir J 2010; 36: 1185-1206
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Solovic I., Sester M., Gomez-Reino J.J., Rieder H.L., Ehlers S., Milburn H.J., Kampmann B., Hellmich B., Groves R., Schreiber S., Wallis R.S., Sotgiu G., Schölvinck E.H., Goletti D., Zellweger J.P., Diel R., Carmona L., Bartalesi F., Ravn P., Bossink A., Duarte R., Erkens C., Clark J., Migliori G.B., Lange C.. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-1206

Member's Comments

No comment yet.

Related content which might interest you: The risk of tuberculosis related to tumour necrosis factor antagonist therapies Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe Year: 2011 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1510-1512 Year: 2015 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1512-1513 Year: 2015 Isoniazid protection and risk of tuberculosis in patients who used anti tumor necrosis factor-alpha treatment Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 281s Year: 2007 QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases Source: Eur Respir J 2009; 33: 586-593 Year: 2009 Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test? Source: International Congress 2015 – Screening strategies in TB Year: 2015 Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014 Tuberculosis and tumor necrosis factor alpha antagonist: Our experience Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Tumour necrosis factor gene polymorphisms and childhood wheezing Source: Eur Respir J 2005; 26: 637-646 Year: 2005 Genetic polymorphism in the human tumor necrosis factor (TNF) and its association with different clinical types of tuberculosis disease in Peruvian patients Source: Eur Respir J 2004; 24: Suppl. 48, 467s Year: 2004 Re-activation of bovine tuberculosis in a patient treated with infliximab Source: Eur Respir J 2008; 32: 229-231 Year: 2008 A screening for latent tuberculosis infection among candidates to anti-tumor necrosis factor-alpha agents using a whole blood interferon-gamma test Source: Annual Congress 2008 - Interferon-gamma release assay tests for diagnosing tuberculosis infection and disease Year: 2008 Using an interferon-γ assay for the diagnosis of tuberculosis infection before using tumor necrosis factor-α blockers Source: Annual Congress 2007 - Gamma-interferon-based tests to diagnose tuberculosis infection and disease Year: 2007 Mould exposure at home relates to inflammatory markers in blood Source: Eur Respir J 2003; 21: 317-322 Year: 2003 Expression levels of membrane-bound tumor necrosis factor alpha receptors in active tuberculosis and healthy individuals Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Latent tuberculosis screening and entering antibody therapy monoclonares against tumor necrosis factor Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016 Tumour necrosis factor and lymphotoxin A polymorphisms: a relationship with COPD and its progression? Source: Eur Respir J 2007; 29: 8-10 Year: 2007